Literature DB >> 8057423

Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.

O Nussbaum1, C C Broder, E A Berger.   

Abstract

The fusogenic activities of enveloped-virus glycoproteins were analyzed by using a quantitative, sensitive, rapid, and highly versatile recombinant vaccinia virus-based assay measuring activation of a reporter gene upon fusion of two distinct cell populations. One population uniformly expressed vaccinia virus-encoded viral glycoproteins mediating specific binding and fusion activities; the other expressed the corresponding cellular receptor(s). The cytoplasm of one population also contained vaccinia virus-encoded bacteriophage T7 RNA polymerase; the cytoplasm of the other contained a transfected plasmid with the Escherichia coli lacZ gene linked to the T7 promoter. When the two populations were mixed, cell fusion resulted in activation of the LacZ gene in the cytoplasm of the fused cells; beta-galactosidase activity was assessed by colorimetric assay of detergent cell lysates or by in situ staining. We applied this approach to study the human immunodeficiency virus type 1 envelope glycoprotein (Env)-CD4 interaction. Beta-Galactosidase was detected within 1 h after cell mixing and accumulated over the next several hours. Cell fusion dependence was demonstrated by the strict requirement for both CD4 and functional Env expression and by the inhibitory effects of known fusion-blocking monoclonal antibodies and pharmacological agents. Quantitative measurements indicated much higher sensitivity compared with analysis of syncytium formation. The assay was used to probe mechanisms of the cell type specificity for Env-CD4-mediated fusion. In agreement with known restrictions, cell fusion occurred only when CD4 was expressed on a human cell type. Membrane vesicle transfer experiments indicated that CD4 initially produced in either human or nonhuman cells was functional when delivered to human cells, suggesting that the fusion deficiency with nonhuman cells was not associated with irreversible defects in CD4. We also demonstrated that the infectivity specificities of different human immunodeficiency virus type 1 isolates for peripheral blood lymphocytes versus continuous CD4+ cell lines were associated with corresponding fusion selectivities of the respective recombinant Env proteins. The assay enabled analysis of the fusogenic activity of the fusion glycoprotein/hemagglutinin-neuraminidase of the paramyxovirus simian virus 5. This system provides a powerful tool to study fusion mechanisms mediated by enveloped-virus glycoproteins, as well as to screen fusion-blocking antibodies and pharmacological agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8057423      PMCID: PMC236941     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

2.  Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.

Authors:  T R Fuerst; E G Niles; F W Studier; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

3.  Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells.

Authors:  P A Ashorn; E A Berger; B Moss
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

5.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.

Authors:  E Helseth; M Kowalski; D Gabuzda; U Olshevsky; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

6.  Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro.

Authors:  M Ito; M Baba; A Sato; R Pauwels; E De Clercq; S Shigeta
Journal:  Antiviral Res       Date:  1987-07       Impact factor: 5.970

7.  Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells.

Authors:  D Rocancourt; C Bonnerot; H Jouin; M Emerman; J F Nicolas
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

8.  Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation.

Authors:  C Cheng-Mayer; M Quiroga; J W Tung; D Dina; J A Levy
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

9.  Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors.

Authors:  C C Broder; P E Kennedy; F Michaels; E A Berger
Journal:  Gene       Date:  1994-05-16       Impact factor: 3.688

10.  Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.

Authors:  M A Skinner; R Ting; A J Langlois; K J Weinhold; H K Lyerly; K Javaherian; T J Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1988-06       Impact factor: 2.205

View more
  172 in total

1.  Induction of syncytia by neuropathogenic murine leukemia viruses depends on receptor density, host cell determinants, and the intrinsic fusion potential of envelope protein.

Authors:  M Chung; K Kizhatil; L M Albritton; G N Gaulton
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Amino acid substitutions within the leucine zipper domain of the murine coronavirus spike protein cause defects in oligomerization and the ability to induce cell-to-cell fusion.

Authors:  Z Luo; A M Matthews; S R Weiss
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  Fusion between retinal rod outer segment membranes and model membranes: functional assays and role for peripherin/rds.

Authors:  K Boesze-Battaglia
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

4.  Mutations in the fusion peptide and adjacent heptad repeat inhibit folding or activity of the Newcastle disease virus fusion protein.

Authors:  T A Sergel; L W McGinnes; T G Morrison
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.

Authors:  P A Zimmerman; A Buckler-White; G Alkhatib; T Spalding; J Kubofcik; C Combadiere; D Weissman; O Cohen; A Rubbert; G Lam; M Vaccarezza; P E Kennedy; V Kumaraswami; J V Giorgi; R Detels; J Hunter; M Chopek; E A Berger; A S Fauci; T B Nutman; P M Murphy
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

6.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.

Authors:  Pin-Fang Lin; Wade Blair; Tao Wang; Timothy Spicer; Qi Guo; Nannan Zhou; Yi-Fei Gong; H-G Heidi Wang; Ronald Rose; Gregory Yamanaka; Brett Robinson; Chang-Ben Li; Robert Fridell; Carol Deminie; Gwendeline Demers; Zheng Yang; Lisa Zadjura; Nicholas Meanwell; Richard Colonno
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

7.  Mutations in multiple domains activate paramyxovirus F protein-induced fusion.

Authors:  Shaguna Seth; Andrew L Goodman; Richard W Compans
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.

Authors:  Cajetan Dogo-Isonagie; Son Lam; Elena Gustchina; Priyamvada Acharya; Yongping Yang; Syed Shahzad-ul-Hussan; G Marius Clore; Peter D Kwong; Carole A Bewley
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

9.  Multivalent interactions with gp120 are required for the anti-HIV activity of Cyanovirin.

Authors:  Yinan Liu; Jacob R Carroll; Lindsey A Holt; James McMahon; Barbara Giomarelli; Giovanna Ghirlanda
Journal:  Biopolymers       Date:  2009       Impact factor: 2.505

10.  Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus.

Authors:  S Bagai; R A Lamb
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.